Challenges of antibody-mediated protection against HIV-1

Expert Review of Vaccines

Volumn 9, Issue 7, 2010, Pages 683-687

  Lewis, George K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; TETANUS TOXOID; VIRUS ENVELOPE PROTEIN;

BINDING SITE; EDITORIAL; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; VIRUS TRANSMISSION;

AIDS VACCINES; ANTIGENS, VIRAL; GENETIC VARIATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 77954662179     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.70     Document Type: Editorial

References (61)

1. Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 422(6929), 307-312 (2003).
2. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100 (7), 4144-4149 (2003).
3. Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgGi subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6(2), 200-206 (2000).
4. Putkonen P, Thorstensson R, Ghavamzadeh L et al. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 352(6334), 436-438 (1991).
5. Emini EA, Schleif WA, Nunberg JH et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355(6362), 728-730 (1992).
6. Mascola JR, Lewis MG, Stiegler G et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73(5), 4009-4018 (1999).
7. Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6(2), 207-210 (2000).
8. Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5(2), 204-210 (1999).
9. Parren PW, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/ human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75(17), 8340-8347 (2001).
10. Prince AM, Reesink H, Pascual D et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retroviruses 7(12), 971-973 (1991).
11. Putkonen P, Thorstensson R, Ghavamzadeh L et al. Prevention of HIV-2 and SI Vsm infection by passive immunization in cynomolgus monkeys. Nature 352, 436-438 (1991).
12. Gardner MB, Rosenthal A, Jennings M, Yee JA, Antipa L, Robinson EJ. Passive immunization of rhesus macques against SI V infection and disease. AIDS Res. Hum. Retroviruses 11, 843-854 (1995).
13. Van Rompay KK, Berardi CJ, Dillard-Telm S et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177(5), 1247-1259 (1998).
14. Joag SV, Li Z, Wang C et al. Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus. AIDS Res. Hum. Retroviruses 15(4), 391-394 (1999).
15. Hessell AJ, Poignard P, Hunter M et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15(8), 951-954 (2009).
16. Hessell AJ, Rakasz EG, Poignard P et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5(5), e1000433 (2009).
17. Hessell AJ, Rakasz EG, Tehrani DM et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10, directed against the human immunodeficiency virus type 1 (HIV-1) gp41 membrane proximal external region (MPER), protect against SHIVBa-L mucosal challenge. J. Virol. 84(3), 1302-1313 (2010).
18. Hofmann-Lehmann R, Rasmussen RA, Vlasak J et al. Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? J. Med. Primatol. 30(4), 190-196 (2001).
19. Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5(2), 204-210 (1999).
20. Nishimura Y, Igarashi T, Haigwood N et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76(5), 2123-2130 (2002).
21. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4(3), 199-210 (2004).
22. Moore JP, Parren PW, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J. Virol. 75(13), 5721-5729. (2001).
23. Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5(3), 233-236 (2004).
24. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28, 413-444 (2010).
25. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6(2), 143-155 (2008).
26. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19-42 (2001).
27. Korber B, Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS4(5), 408-417 (2009).
28. Guan Y, Sajadi MM, Kamin-Lewis R et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc. Natl Acad. Sci. USA 106(10), 3952-3957 (2009).
29. Liao HX, Levesque MC, Nagel A et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol Methods 158(1-2), 171-179 (2009).
30. Scheid JF, Mouquet H, Feldhahn N et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238), 636-640 (2009).
31. Walker LM, Phogat SK, Chan-Hui PY et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950), 285-289 (2009).
32. Corti D, Langedijk JP, Hinz A et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5(1), e8805 (2010).
33. Crooks ET, Moore PL, Richman D et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum. Antibodies 14(3-4), 101-113 (2005).
34. Polonis VR, Brown BK, Rosa Borges A et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375 (2), 315-320 (2008) .
35. Mann AM, Rusert P, Berlinger L, Kuster H, Gunthard HF, Trkola A. HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 23(13), 1659-1667 (2009) .
36. Fenyo EM, Heath A, Dispinseri S et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4(2), e4505 (2009).
37. Gomez-Roman VR, Patterson LJ, Venzon D et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SI Vmac251. J. Immunol. 174(4), 2185-2189 (2005).
38. DeVico A, Fouts T, Lewis GK et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl Acad. Sci. USA 104(44), 17477-17482 (2007).
39. Hidajat R, Xiao P, Zhou Q et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 83(2), 791-801 (2009).
40. Li A, Baba TW, Sodroski J et al. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum. Retroviruses 13(8), 647-656 (1997).
41. Mascola JR, Louder MK, VanCott TC et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71(10), 7198-7206 (1997).
42. Mascola JR, Lewis MG, Stiegler G et al. Protection of macaques against pathogenic simian/human immunodefiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009-4018 (1999).
43. Parren PW, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/ human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75(17), 8340-8347 (2001).
44. Nishimura Y, Igarashi T, Haigwood N et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76(5), 2123-2130 (2002).
45. Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158), 101-104 (2007).
46. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75(24), 12161-12168 (2001).
47. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 4(5), 388-393 (2009)
48. Xiao P, Zhao J, Patterson LJ et al. Multiple vaccine-elicited non-neutralizing anti-envelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following SHIV89.6P challenge in rhesus macaques. J. Virol. DOI: 10.1128/JVI.00410-10 (2010) (Epub ahead of print).
49. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178(10), 6596-6603 (2007).
50. Shen R, Drelichman ER, Bimczok D et al. GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J. Immunol. 184(7), 3648-3655 (2010).
51. Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J. Virol. 67(1), 53-59 (1993).
52. Bonsignori M, Moody MA, Parks RJ et al. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol. 183(4), 2708-2717 (2009).
53. Nishimura Y, Igarashi T, Haigwood NL et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl Acad. Sci. USA 100(25), 15131-15136 (2003).
54. Ferrantelli F, Buckley KA, Rasmussen RA et al. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology 358(1), 69-78 (2007)
55. Manca N, di Marzo Veronese F, Ho DD, Gallo RC, Sarngadharan MG. Sequential changes in antibody levels to the env and gag antigens in human immunodeficiency virus infected subjects. Eur. J. Epidemiol. 3(2), 96-102 (1987).
56. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357(19), 1903-1915 (2007).
57. Vigerust DJ, Shepherd VL. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 15(5), 211-218 (2007).
58. Finzi A, Xiang SH, Pacheco B et al. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell. 37(5), 656-667 (2010).
59. Pancera M, Majeed S, Ban YE et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl Acad. Sci. USA 107(3), 1166-1171 (2010).
60. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr. Opin Immunol. 11(2), 172-179 (1999).
61. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).